-
Media Release
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
-
Media Release
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
-
Media Release
Pluvicto® demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
-
Media Release
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
-
Media Release
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
-
Media Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto™ in metastatic hormone-sensitive prostate cancer
-
Media Release
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
-
Media Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
-
Media Release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
-
Media Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
-
Media Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
-
Media Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients